GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
admin 23rd October 2017 Uncategorised 0Despite being one of the most expensive drugs in the world, GlaxoSmithKline’s gene therapy Strimvelis won the backing of the often stingy U.K. cost watchdogs to treat a rare disease called ADA-SCID, or “bubble boy” syndrome. The drug, which costs €594,000 (about $700,000), is a one-time treatment that the overseers said is worth the money because of survival rates and other benefits.
More: GlaxoSmithKline picks up NICE recommendation for Strimvelis, a €594,000 gene therapy
Source: fierce